The company plans to submit a new drug application for tavapadon to the US Food and Drug Administration next year.
“The positive results across all three Phase 3 TEMPO trials underscore the potential of tavapadon as a first-in-class D1/D5 ...
The North Chicago-based drugmaker said it's received positive topline results in a Phase 3 trial of its investigational ...
Hello from San Diego, where I always happen to be, but where this weekend I had the delight of hanging out with coworkers ...
Treatment with tavapadon led to a statistically significant improvement in motor function compared with placebo. Topline results were announced from a phase 3 trial evaluating tavapadon, a selective ...
AbbVie Inc. is a strong investment opportunity with promising drugs, steady dividends, and attractive growth potential. Find ...